NAD(P)H Oxidase in the Failing Human Heart
With great interest we read the recent JACC editorial comment by Warnholtz and Munzel (1) in which they emphasize the importance of NAD(P)H-derived reactive oxygen species in heart failure. This comment was for the greater part inspired by the interesting study by Heymes et al. (2) published in the same issue of JACC, which shows by immunohistochemistry that gp91 phox is expressed in human cardiomyocytes.
In their editorial comment, Warnholtz and Munzel state that Heymes et al. (2) for the first time provide evidence of the activation and expression of the NAD(P)H oxidase in human cardiomyocytes. However, in March 2003 we already published a study in which we provided evidence for the expression of gp91 phox (Nox2) in human cardiomyocytes (3) . This was proven not only by immunohistochemistry but also by Western blot analysis on isolated human cardiomyocytes instead of total-tissue homogenates.
Although both studies describe the expression of Nox2 in human cardiomyocytes, there are some differences. For example, Heymes et al. (2) show by Western blot on total-tissue homogenates that there is no difference in Nox2 expression between failing and nonfailing hearts, whereas we demonstrated by immunohistochemistry that the number of Nox2-expressing cardiomyocytes within the infarction area is significantly increased after acute myocardial infarction (AMI). We have to keep in mind, however, that with AMI we have studied an acute phenomenon, whereas congestive heart failure (CHF) is a more or less chronic process. This might explain the interesting differences in the pattern of Nox2 expression between acute and chronic heart disease and could point to a different regulation of Nox2 expression in both phenomena.
The data of Heymes et al. (2) therefore, corroborate our own findings in that we both, using different antibodies, show that Nox2 is expressed in human cardiomyocytes. Their measured increase in NAD(P)H oxidase activity after CHF and our increased Nox2 expression after AMI emphasize the role of the NAD(P)H oxidase(s) in human cardiovascular pathophysiology. We completely agree with Warnholtz and Munzel that the possible co-expression of other Nox isoforms, the functional contribution of the cardiomyocyte-specific oxidases to the ROSmediated effects observed in cardiac tissue homogenates, and the search for possibilities of pharmacological intervention are important issues that need to be addressed now.
REPLY
In our recent editorial (1) we commented on the expression and activity of the NAD(P)H oxidase subunit gp91 phox isoform in the failing human heart reported by Heymes et al. (2) . We also stated that this evidence was provided for the first time, not mentioning the article by Krijnen et al. (3) , which was published in the March issue of the Journal of Clinical Pathology. One simple reason for that was that our editorial comment was already in press when the report from Krijnen et al. appeared. In that study the investigators describe the existence of Nox 2 (gp91 phox ) in normal human cardiomyocytes and an up-regulation of the expression as assessed by Western blotting technique and by immunohistochemistry in viable and jeopardized cardiomyocytes of freshly infarcted areas. Since this report was published in March, we agree that the study was indeed the first to comment on the expression of the NAD(P)H oxidase subunit Nox2 in human cardiomyocytes. Although the researchers have observed an increase in Nox2 in myocardial areas subject to acute myocardial infarction (AMI), one cannot really compare this situation with that of chronic congestive heart failure. Acute myocardial infarction is always accompanied by an acute and severe inflammatory response, and in the studies by Krijnen et al. no data were provided as to whether these patients had clinical signs of acute heart failure. Thus, the correspondent may agree that Heymes et al. (2) provided the first evidence for a lack of changes in the expression of Nox2 but an increase in the activity of the enzyme in patients with severe chronic congestive heart failure. 
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